



## Accreditation

### Internet Activity Accreditation

- **Title of the activity:** Clinical Endocrinology Update 2022 Recordings
- Jointly provided by Postgraduate Institute for Medicine and the Endocrine Society
- Release date: 11/03/2022
- Expiration date: 09/10/24
- Estimated time to complete activity: [33] hours
- Mechanism for the learner to contact PIM [inquiries@pimed.com](mailto:inquiries@pimed.com).



The Endocrine Society designates this activity for a maximum of 33 *AMA PRA Category 1 Credits™*\*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*\* Please note that while other accrediting bodies accept AMA PRA Category 1 Credit™, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.*



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 29.75 Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

## Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Endocrine Society. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Credit Designation

### Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 33.00 contact hours. Designated for 6.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

### Continuing Physician Assistant Education



Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 33.00 AAPA Category 1 CME credits. Approval is valid until September 10<sup>th</sup>, 2024. PAs should only claim credit commensurate with the extent of their participation.

## Method of Participation and Request for Credit

In order to obtain your CME/CE certificate, please follow the steps below at the conclusion of the activity:

1. Go to [www.cmeuniversity.com](http://www.cmeuniversity.com)
2. Login or Create a New Account (will take less than 1 minute)
  - a. If you receive a message when creating a new account that “the email you entered is already in use”, please click the [Forgot my Username or Password](#) link to have your Username and Password sent to you via email
  - b. After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3. Type in **17326** at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter
4. Click on the activity title when it appears
5. Choose the type of credit you desire
6. Complete the online assessment
7. Receive an immediate CME/CE Certificate to download and/or print for your files

If you have questions regarding the certification of this activity, please contact PIM via email at [inquiries@pimed.com](mailto:inquiries@pimed.com).

### **Disclosure of Unlabeled Use**

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for a discussion of approved indications, contraindications, and warnings.

### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

### **Target Audience**

This activity is intended for Endocrinologists engaged in the care of patients with endocrine-related diseases in primary care, hospital, managed care organizations, and ambulatory care.

### **Educational Objectives**

*After completing this activity, the participant should be better able to:*

- Demonstrate updated knowledge of pathophysiology, diagnosis, and treatment of diabetes, lipid & obesity, adrenal, Calcium & bone, pituitary, thyroid, transgender care, and reproductive endocrine disorders.
- Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae.
- Apply updated knowledge and clinical skills in improving patient care.

### **Faculty**

#### **Adrenal**

Amir Hamrahian, MD (Johns Hopkins University)

Tobias Else, MD (University of Michigan)

Celso Gomez-Sanchez, MD (University of Mississippi Medical Center)

#### **Calcium & Bone**

Benjamin Leder, MD (Massachusetts General Hospital)

Peter Tebben, MD (Mayo Clinic)

Pouneh Fazeli, MD, MPH (University of Pittsburgh)

Aliya Khan, MD, FRCP, FACP (McMaster University)

## **Diabetes**

Sarit Polsky, MD, MPH (University of CO Anschutz Medical Campus)

Rodica Pop-Busui, MD, PhD (University of Michigan)

Joshua Joseph, MD, PhD, FAHA (The Ohio State University Wexner Medical Center)

Rodolfo Galindo, MD (Emory University)

Matthew Gilbert, DO, MPH (University of Vermont College of Medical)

Harpreet Bajaj, MD, MPH (LMC Healthcare)

Viral Shah, MD (University of Colorado)

## **Female Reproduction**

Frances Hayes, MB, BCh, BAO (Massachusetts General Hospital)

## **Male Reproduction**

Arthi Thirumalai, MBBS (University of Washington)

## **Lipids & Obesity**

Jaime Almandoz, MD, MBA, FTOS (UT Southwestern Medical Center)

Monique Hassan, MD (Baylor Scott and White)

Marc-Andre Cornier, MD (Medical University of South Carolina)

## **Pituitary**

Gabriel Zada, MD (University of Southern California)

Diane Donegan, MB BCh BAO, MRCPI (Indiana University)

Dr. Adriana Ioachimescu, MD, PhD (Emory University)

Lynnette Nieman, MD (The National Institutes of Health)

## **Thyroid**

Alan Ho, MD, PhD (Memorial Sloan Kettering Cancer Center)

Whitney Goldner, MD (University of Nebraska Medical Center)

Spyridoula Maraka, MD (University of Arkansas for Medical Sciences Endocrine Fellowship Program)

Sanziana Roman, MD, FACS, DABS (University of California San Francisco)

## Transgender Care

Jeffrey D. Zajac AO, MBBS, PHD, FRACP (University of Melbourne, Austin Health)

### Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Peter Tebben, MD (Mayo Clinic)

Grant Recipient: Ultragenyx

Pouneh Fazeli, MD, MPH (University of Pittsburgh)

No relevant financial relationships

Benjamin Leder, MD (Massachusetts General Hospital)

Consulting Fee: Radius Health Inc

Aliya Khan, MD, FRCP, FACP, FACE (McMaster University)

Speaker: Alexion Pharmaceuticals Inc.

Speaker: Amgen Inc

Speaker: Shire

Speaker: Takeda

Speaker: Ultragenyx

Speaker: Chugai

Consulting Fee: Alexion Pharmaceuticals Inc.

Consulting Fee: Amgen Inc

Consulting Fee: Radius Health Inc

Consulting Fee: Shire

Consulting Fee: Takeda

Consulting Fee: Ultragenyx

Consulting Fee: Ascendis, Amolyt, Chugai

Grant Recipient: Alexion Pharmaceuticals Inc.

Grant Recipient: Amgen Inc

Grant Recipient: Radius Health Inc

Grant Recipient: Shire

Grant Recipient: Takeda

Grant Recipient: Ultragenyx

Grant Recipient: Ascendis, Amolyt, Chugai

Celso Gomez-Sanchez, MD (University of Mississippi Medical Center)

No relevant financial relationships

Tobias Else, MD (University of Michigan)

Advisory Board Member: Corcept Therapeutics

Advisory Board Member: HRA Pharmaceuticals

Advisory Board Member: Merck

Advisory Board Member: Lantheus

Amir Hamrahian, MD (Johns Hopkins University)

Consulting Fee: Corcept

Consulting Fee: Recordati Rare Diseases

Grant Recipient: Corcept

Advisory Board Member: Corcept

Advisory Board Member: HRA Pharmaceuticals

Advisory Board Member: Xeris Pharmaceuticals

Sarit Polsky, MD, MPH (University of CO Anschutz Medical Campus)

Relationship: Commercial Interest(s)

Advisory Board Member: Medtronic Minimed

Grant Recipient: Dexcom

Grant Recipient: Medtronic Minimed

Rodica Pop-Busui, MD, PhD (University of Michigan)

Advisory Board Member: Averitas Pharma

Advisory Board Member: Nevro Corporation

Consulting Fee: Novo Nordisk

Joshua Joseph, MD, PhD, FAHA (The Ohio State University Wexner Medical Center)

No relevant financial relationships

Matthew Gilbert, DO, MPH (University of Vermont College of Medical)

No relevant financial relationships

Rodolfo Galindo, MD (Emory University)

Consulting Fee: Bayer Inc.

Consulting Fee: Boehringer Ingelheim

Consulting Fee: Eli Lilly & Company

Consulting Fee: Sanofi

Grant Recipient: Dexcom

Grant Recipient: Eli Lilly & Company  
Grant Recipient: Novo Nordisk

Harpreet Bajaj, MD, MPH (LMC Healthcare)

No relevant financial relationships

Viral Shah, MD (University of Colorado)

Relationship: Commercial Interest(s)  
Advisory Board Member: Eli Lilly & Company  
Advisory Board Member: Novo Nordisk  
Advisory Board Member: Sanofi-Aventis  
Advisory Board Member: VTV Therapeutics  
Advisory Board Member: Medscape. Lifescan  
Grant Recipient: Dexcom  
Grant Recipient: Insulet Corporation  
Grant Recipient: Tandem Diabetes Care  
Speaker: Dexcom  
Speaker: Insulet Corporation

Frances Hayes, MB, BCh, BAO (Massachusetts General Hospital)

No relevant financial relationships

Arthi Thirumalai, MBBS (University of Washington)

No relevant financial relationships

Jeffrey D. Zajac AO, MBBS, PHD, FRACP (University of Melbourne, Austin Health)

No relevant financial relationships

Jaime Almandoz, MD, MBA, FTOS (UT Southwestern Medical Center)

Relationship: Commercial Interest(s)  
Advisory Board Member: Eli Lilly & Company  
Advisory Board Member: Novo Nordisk

Monique Hassan, MD (Baylor Scott and White)

No relevant financial relationships

Marc-Andre Cornier, MD (Medical University of South Carolina)

Relationship: Commercial Interest(s)  
Grant Recipient: Boehringer Ingelheim  
Grant Recipient: Novartis Pharmaceuticals  
Grant Recipient: Rhythm  
Advisory Board Member: Novo Nordisk  
Advisory Board Member: Regeneron Pharmaceuticals

Advisory Board Member: LetsGetChecked

Gabriel Zada, MD (University of Southern California)

No relevant financial relationships

Diane Donegan, MB BCh BAO, MRCPI (Indiana University)

Relationship: Commercial Interest(s)

Advisory Board Member: Recordati

Consulting Fee: Corcept

Adriana Ioachimescu, MD, PhD (Emory University)

Relationship: Commercial Interest(s)

Consulting Fee: HRA Pharmaceuticals

Consulting Fee: Ipsen

Consulting Fee: Recordati Rare Disease, Strongbridge/Xeris Pharmaceutical, Chiasma, Inc/Amryt Pharma

Grant Recipient: Principal investigator for institution-directed research for multicentric clinical trials sponsored by Strongbridge/Xeris Pharmaceutical, Chiasma, Inc/Amryt Pharma and Recordati Rare Disease

Lynnette Nieman, MD (The National Institutes of Health)

Relationship: Commercial Interest(s)

Grant Recipient: Up To Date

Spyridoula Maraka, MD (University of Arkansas for Medical Sciences Endocrine Fellowship Program)

No relevant financial relationships

Sanziana Roman, MD, FACS, DABS (University of California San Francisco)

No relevant financial relationships

Whitney Goldner, MD (University of Nebraska Medical Center)

No relevant financial relationships

Alan Ho, MD, PhD (Memorial Sloan Kettering Cancer Center)

Relationship: Commercial Interest(s)

Advisory Board Member: Elevar Therapeutics

Advisory Board Member: Prelude Therapeutics, Affyimmune

Advisory Board Member: Eisai

Advisory Board Member: Exelixis Inc.

Advisory Board Member: Rgenta Therapeutics, Kura Oncology, Inxmed, Prelude Therapeutics

The Postgraduate Institute for Medicine planners and others have nothing to disclose. The Endocrine Society planners and others have nothing to disclose.